GLP-1 Side Effects & Safety

By Michael Wright

Most people who start GLP-1 therapy experience some side effects, particularly in the early weeks of treatment. The majority are gastrointestinal, predictable, and manageable. But knowing what to expect, why it happens, and when to take something seriously makes the adjustment period considerably easier to navigate.

What Are the Most Common GLP-1 Side Effects?

GLP-1 medications share a class-level side effect profile, meaning most of the effects below apply across semaglutide and tirzepatide rather than being specific to one product. Individual rates and severity differ between medications and between patients.

Side Effect	How Common	Notes
Nausea	Very common	Most frequent early side effect; usually peaks in first 1-3 weeks
Constipation	Common	Often related to reduced food intake and slowed gut motility
Diarrhea	Common	May alternate with constipation in some patients
Vomiting	Common	More likely after dose increases; usually brief
Acid reflux/heartburn	Common	Related to slowed gastric emptying
Reduced appetite	Very common	Intended effect; can feel excessive at higher doses
Fatigue	Common early	Usually temporary; often reflects metabolic adjustment
Mild headache	Occasionally reported	Often linked to hydration changes
Injection site reactions	Occasionally reported	Redness, itching or mild swelling at injection site
Burping	Occasionally reported	Related to slowed gastric emptying

Tirzepatide and semaglutide have broadly similar GI side effect profiles, though rates vary in clinical trials. Both are significantly better tolerated when dose titration is gradual rather than accelerated.

Why Do GLP-1 Side Effects Happen?

Most GLP-1 side effects aren't random reactions; they're predictable consequences of how the medications work. Understanding the mechanism behind them makes them easier to anticipate and manage.

Slowed gastric emptying is the primary driver of GI symptoms. GLP-1 receptor activation in the stomach slows the movement of food into the small intestine. For a digestive system accustomed to a different pace, this adjustment produces nausea, bloating, acid reflux, and burping: particularly in the early weeks of treatment or after dose increases.

Reduced food intake affects gut function. Eating less means less fiber, less water from food, and fewer calories passing through the digestive tract. Constipation is often partly a consequence of eating less rather than a direct drug effect. This is why hydration and dietary fiber become more important during treatment.

Dose titration creates temporary spikes in side effect intensity. GLP-1 protocols start at a low dose and increase gradually for a reason. Each step up in dose briefly intensifies the same effects that produced side effects early in treatment. Symptoms that had settled often return temporarily after a dose increase before the body adjusts again.

Rapid eating amplifies nausea. GLP-1 medications slow gastric emptying; eating quickly loads the stomach faster than it can now empty. The combination reliably produces nausea, and slowing down at meals is one of the most effective practical adjustments patients can make.

Not every symptom is caused by the medication. Fatigue, headache, and general unwellness in the first few weeks often reflect dehydration, reduced caloric intake, or normal metabolic adjustment rather than a direct drug reaction. Separating medication effects from the effects of eating significantly less (possibly for the first time in years) isn't always straightforward.

How Long Do Side Effects Last?

There's no fixed timeline that applies to every patient, but a few general patterns hold across most clinical experience with these medications.

The first one to four weeks of GLP-1 treatment are typically when GI side effects are most pronounced. Nausea, in particular, tends to peak in this window as the body adjusts to slowed gastric emptying. For most patients, symptoms improve meaningfully before the end of the first month: not necessarily disappearing, but becoming considerably more manageable.

After dose increases, expect a temporary return of earlier symptoms. Each titration step briefly recreates the adjustment the body went through at the start. This usually lasts days to a couple of weeks rather than the full adjustment period of the initial dose.

By months two and three, most patients report that GI side effects have settled to a level they can manage comfortably, or have resolved almost entirely. Constipation can be more persistent than nausea and may require ongoing dietary attention throughout treatment. (Remember to hydrate!)

For a smaller number of patients, side effects remain more disruptive beyond the typical adjustment window. In those cases, dose adjustment, slower titration, or a change in how and when the medication is taken can often help: all of which are reasons to stay in contact with your clinical care team rather than waiting it out alone. (Remember, the Lttl care team is available to you throughout your treatment program at no additional charge.)

How to Reduce or Manage Common Side Effects

Most GLP-1 side effects respond well to practical adjustments. These aren't workarounds: they're evidence-informed strategies that most patients find genuinely useful.

For nausea:

Eat smaller meals and slow down while eating. This is the single most effective intervention for most patients.

Avoid high-fat, heavily spiced, and fried foods, particularly in the early weeks. These foods slow gastric emptying on their own, and adding a GLP-1 medication compounds the effect.

Don't lie down immediately after eating. Staying upright for at least an hour after meals helps.

If your nausea hits at its worst in the morning, try eating something small before getting out of bed.

Take the medication at a time that minimizes disruption. Some patients do better injecting at night so the peak effect occurs during sleep.

For constipation:

Increase dietary fiber intentionally. Remember, reduced food intake often reduces fiber intake, too.

Prioritize hydration throughout the day, not just when you feel thirsty. GLP-1 medications can blunt thirst cues.

A fiber supplement can help if dietary adjustments aren't sufficient.

For acid reflux:

Avoid eating close to bedtime.

Limit carbonated beverages, which can worsen reflux when gastric emptying is slowed.

Elevating the head of the bed slightly helps some patients with overnight reflux.

For fatigue:

Ensure adequate protein intake. Eating less without being deliberate about protein quality accelerates muscle loss and compounds fatigue.

Monitor electrolytes. Sodium, potassium, and magnesium all drop with reduced food intake and can contribute significantly to tiredness and headache.

Important: Do not adjust your dose based on side effects without talking to your clinician first. Dose timing and titration changes can meaningfully affect your experience, but those decisions should be made with clinical input and not independently. The Lttl care team is available exactly for situations like this.

Serious Symptoms and When to Seek Medical Help

Most GLP-1 side effects are mild and resolve without intervention. The following symptoms are different. They require prompt attention and should not be waited out.

Symptom	Possible Concern	What to Do
Severe or persistent abdominal pain, especially radiating to the back	Pancreatitis	Stop medication and seek emergency care immediately
Upper right abdominal pain, fever, or jaundice (yellowing of skin or eyes)	Gallbladder disease	Contact your clinician promptly or seek urgent care
Rapid or irregular heartbeat	Possible cardiac reaction	Contact your clinician or seek urgent care
Signs of a serious allergic reaction: swelling of face, lips, tongue or throat; difficulty breathing; severe rash	Hypersensitivity reaction	Seek emergency care immediately
Vision changes or loss	Possible diabetic retinopathy complication	Contact your clinician promptly
Symptoms of low blood sugar: shakiness, sweating, confusion, rapid heartbeat	Hypoglycemia (more likely if also taking insulin or sulfonylureas)	Treat low blood sugar per your clinician's guidance; seek care if severe
Severe or persistent vomiting with inability to keep fluids down	Dehydration risk	Contact your clinician; seek urgent care if unable to hydrate
Thoughts of suicide or self-harm	Rare reported signal (under ongoing FDA monitoring)	Contact a mental health professional or crisis line immediately

GLP-1 medications also carry a boxed warning (the FDA's most serious warning level) for a potential risk of thyroid C-cell tumors, based on animal studies. This risk has not been confirmed in humans, but GLP-1 medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your clinician about any neck swelling, hoarseness, difficulty swallowing, or shortness of breath.

Follow the patient information included with your specific medication, and contact your prescribing clinician or care team with any symptom that feels unusual or concerning.

Who May Have a Higher Risk of Problems?

Certain patients require additional caution before starting GLP-1 therapy. These are not automatic disqualifiers, but they're factors a clinician needs to know about and evaluate.

Personal or family history of medullary thyroid carcinoma (MTC) or MEN2. These are contraindications: GLP-1 medications should not be used in patients with this history.

History of pancreatitis. GLP-1 medications have been associated with pancreatitis risk. Patients with a prior episode require careful evaluation before starting.

Gallbladder disease or a history of gallstones. Rapid weight loss and GLP-1 therapy have both been independently associated with increased gallstone risk. Patients with relevant history should discuss this with their clinician.

Gastroparesis or severe gastrointestinal motility disorders. Because GLP-1 medications slow gastric emptying, they are generally avoided in patients with existing gastroparesis (a condition where the stomach already empties too slowly).

Patients taking insulin or sulfonylureas. Combining GLP-1 therapy with these blood sugar-lowering medications increases the risk of hypoglycemia. Dose adjustments to existing diabetes medications are often needed and should be clinician-directed.

Patients taking oral medications with narrow therapeutic windows. Slowed gastric emptying can affect the absorption timing of some oral drugs. A full medication review before starting is essential.

Pregnancy, planned pregnancy, or breastfeeding. GLP-1 medications are not evaluated for safety in pregnancy and are generally discontinued before conception is attempted. Animal studies have shown fetal harm.

Patients with a history of severe eating disorders. The appetite-suppressing effects of GLP-1 medications may complicate recovery in patients with a history of restrictive eating patterns. Clinical evaluation of appropriateness is particularly important in this population.

Patients with a history of suicidality or significant mood disorders. A small signal of suicidal ideation has been reported in post-market surveillance data and remains under FDA review. Clinicians should be aware of psychiatric history when evaluating eligibility.

None of these factors should be self-assessed as a reason to avoid or proceed with treatment. Eligibility requires clinical evaluation and full disclosure of relevant history to your care team.

Frequently Asked Questions

Are GLP-1 Side Effects Worse With Tirzepatide Than Semaglutide?

The two medications have similar GI side effect profiles, and head-to-head data doesn't clearly establish that one is better tolerated than the other across the board. Tirzepatide's slightly faster standard titration may produce more pronounced early symptoms in some patients, but individual experience varies significantly. Tolerability is one of the factors a clinician considers when recommending one medication over the other.

Can GLP-1 Medications Cause Hair Loss?

Hair loss (telogen effluvium) has been reported by some patients on GLP-1 therapy, but it's not listed as a common side effect in the prescribing information for semaglutide or tirzepatide. When it does occur, it's generally thought to be a consequence of rapid weight loss and reduced nutritional intake rather than a direct drug effect: the same pattern seen with other significant caloric restriction. Adequate protein intake and nutritional support during treatment appear to reduce the likelihood.

Do GLP-1 Medications Affect Mental Health?

The relationship between GLP-1 medications and mental health has been an active area of research and regulatory review. Earlier versions of the Wegovy and Zepbound prescribing labels included a warning about suicidal behavior and ideation, but the FDA removed that warning in January 2026 following a review that did not establish a causal link between GLP-1 medications and suicidality.

That said, mental health is still worth discussing with your clinician before starting treatment. Some patients report improved mood during treatment, possibly related to improved metabolic health, reduced food preoccupation, and the psychological benefits of meaningful weight loss. Others noticed mood changes, particularly during the adjustment period. Patients with a history of depression, anxiety, or other mood disorders should disclose that history during the intake process and stay in contact with their care team if they notice any changes during treatment.

As with any prescription medication, your clinician is the right person to assess whether GLP-1 therapy is appropriate given your individual mental health history.

Can You Drink Alcohol While Taking GLP-1 Medications?

Alcohol isn't absolutely contraindicated with GLP-1 medications, but there are a few practical considerations worth knowing. Slowed gastric emptying can affect how quickly alcohol is absorbed, potentially making effects more unpredictable. Alcohol is also dehydrating, which amplifies the hydration challenges already present with GLP-1 therapy. And if you're taking blood sugar-lowering medications alongside a GLP-1, alcohol can increase the risk of hypoglycemia. Moderate consumption is a reasonable discussion to have with your clinician rather than a blanket rule.

What Should I Do If I Miss a Dose?

For once-weekly injectable semaglutide and tirzepatide: if your next scheduled dose is more than two days away, take the missed dose as soon as you remember. If your next dose is within two days, skip the missed dose and resume your regular schedule. Do not take two doses to make up for a missed one. When in doubt, follow the instructions included with your medication or contact your care team. Your Lttl team is available for exactly this kind of question.

Will Side Effects Come Back if I Stop and Restart Treatment?

Yes, typically. If you stop GLP-1 therapy and restart after a gap, your body will go through an adjustment period similar to when you first started. Restarting at a high dose after a gap is more likely to produce significant side effects than resuming at a lower dose and re-titrating. This is another reason to involve your clinician in any decision to pause or stop treatment rather than making that call independently.

Bibliography

• Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
• Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
• U.S. Food and Drug Administration. (2024). Highlights of prescribing information: Wegovy (semaglutide) injection. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdf
• U.S. Food and Drug Administration. (2025). Highlights of prescribing information: Zepbound (tirzepatide) injection. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215866s039lbl.pdf
• Drucker, D. J. (2022). GLP-1 physiology informs the pharmacotherapy of obesity. Molecular Metabolism, 57, 101351. https://pubmed.ncbi.nlm.nih.gov/34626851/
• Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017). Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism, 19(9), 1242-1251. https://dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.12932